DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.
This drug has eighteen patent family members in nine countries.
The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.
Tauvid will be eligible for patent challenges on May 28, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 19, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAUVID
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TAUVID
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAUVID
Identify potential brand extensions & 505(b)(2) entrants
|Avid Radiopharmaceuticals||Phase 1|
|Avid Radiopharmaceuticals||Early Phase 1|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Avid Radiopharms Inc||TAUVID||flortaucipir f-18||SOLUTION;INTRAVENOUS||212123-001||May 28, 2020||RX||Yes||Yes||⤷ Try it Free||⤷ Try it Free||Y||⤷ Try it Free|
|Avid Radiopharms Inc||TAUVID||flortaucipir f-18||SOLUTION;INTRAVENOUS||212123-002||May 28, 2020||RX||Yes||Yes||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|Avid Radiopharms Inc||TAUVID||flortaucipir f-18||SOLUTION;INTRAVENOUS||212123-001||May 28, 2020||RX||Yes||Yes||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Country||Patent Number||Estimated Expiration|
|European Patent Office||2852572||⤷ Try it Free|
|South Korea||20100135235||⤷ Try it Free|
|World Intellectual Property Organization (WIPO)||2013176698||⤷ Try it Free|
|>Country||>Patent Number||>Estimated Expiration|